Delving into the Latest Updates on Acyclovir with Synapse

Overview

Basic Info

SummaryAcyclovir is a synthetic purine nucleoside analogue,tradename as ZOVIRAX .Acyclovir has in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV).The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In vitro, acyclovir triphosphate stops replication of herpes viral DNA. ZOVIRAX (acyclovir) is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients。Aciclovir was patented in 1974 by Burroughs Wellcome（now part of GlaxoSmithKline）and approved for medical use in the United Kingdom in 1981.

Drug Type

Small molecule drug

Synonyms

Aciclovir, Aciclovir (JP17/INN), Acycloguanosine

+ [44]

Target

DNA-directed DNA polymerase

Action

inhibitors

Mechanism

DNA-directed DNA polymerase inhibitors

Therapeutic Areas

Infectious DiseasesNervous System DiseasesEye Diseases+ [4]

Active Indication

Keratitis, HerpeticChickenpoxEncephalitis, Herpes Simplex+ [5]

Inactive Indication

Originator Organization

Burroughs Wellcome

Active Organization

Pfizer Australia Pty Ltd.

TAD Pharma GmbH

KYUNG DONG PHARMACEUTICAL Co., Ltd

+ [6]

Inactive Organization

Pharmobedient Consulting LLCGlaxo Wellcome Plc

GSK Plc

+ [5]

License Organization

Valerio Therapeutics SA

Medivir AB

Vectans Pharma SA

+ [4]

Drug Highest PhaseApproved

First Approval Date

United Kingdom (01 Jan 1981),

Herpes Simplex

RegulationOrphan Drug (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC8H11N5O3

InChIKeyMKUXAQIIEYXACX-UHFFFAOYSA-N

CAS Registry59277-89-3

This is a multicenter, prospective, randomized, controlled trial. A total of 165 patients with idiopathic trigeminal neuralgia will be enrolled and randomly divided into three groups at a 1:1:1 ratio. The aim is to compare the efficacy and safety of conventional carbamazepine monotherapy, carbamazepine combined with oral antiviral therapy, and carbamazepine combined with anti-inflammatory therapy in pain relief, quality of life improvement and adverse event profiles.

Start Date31 Aug 2026

Sponsor / Collaborator

Beijing Tiantan Hospital

[+1]

100 Clinical Results associated with Acyclovir

Login to view more data

100 Translational Medicine associated with Acyclovir

Login to view more data

100 Patents (Medical) associated with Acyclovir

Login to view more data

10,639

Literatures (Medical) associated with Acyclovir

31 Dec 2026·Human Vaccines & Immunotherapeutics

Multifocal mucocutaneous herpes simplex virus type 1 infection temporally associated with seasonal influenza vaccination in a young adult without a known immunocompromising condition: A case report

Article

Author: Hung, Pei-Lun ; Liu, Yen-Hung

Seasonal influenza vaccination is widely implemented and generally safe; however, rare immunological adverse events have been reported. We describe a case of multifocal mucocutaneous Herpes simplex virus type 1 (HSV-1) infection temporally associated with seasonal influenza vaccination in a 28-year-old man without a known immunocompromising condition. Seven days after vaccination, he developed oral ulcerative lesions and multiple vesicular eruptions involving the anterior chest wall, pubic region, and penile shaft. A multiplex polymerase chain reaction assay performed on specimens obtained from clinically apparent lesions detected HSV-1 DNA, whereas HSV-2 and other sexually transmitted pathogens included in the assay were not detected. Intravenous acyclovir was administered, resulting in complete clinical resolution. Although causality cannot be established, the close temporal relationship between influenza vaccination and the onset of HSV-1 infection is noteworthy, while alternative explanations cannot be excluded. This case highlights the importance of considering HSV infection in the differential diagnosis of multifocal mucocutaneous lesions occurring after influenza vaccination without implying a causal relationship.

01 Dec 2026·JOURNAL OF NEUROVIROLOGY

Varicella zoster virus meningitis with a dermatomal rash in immunocompetent hosts: a systematic review and novel case report

Review

Author: Naz, Sumayya ; Dusseau, Nathaniel B ; Razzaque, Joyeta ; Theeb, Ahmed Ba ; Ali, Aizaz

Abstract:

Varicella zoster virus (VZV) reactivation with central nervous system (CNS) involvement is an uncommon but important cause of lymphocytic meningitis in both immunocompromised and immunocompetent individuals. While cranial presentations, especially V1 involvement, are well documented, spinal-dermatomal VZV meningitis is rarely reported. We conducted a systematic review of PubMed, Scopus, and Embase using PRISMA guidelines to identify all cases of laboratory-confirmed VZV meningitis or encephalitis with a dermatomal rash in immunocompetent adults affecting spinal levels C1 and below. Data extracted included demographics, dermatome distribution, CSF findings, treatment, and outcomes. We also report a novel case from our institution involving isolated C4–C5 involvement. Seventeen total cases met inclusion, including our 44-year-old male patient who presented with fever, severe headache, and a right-sided vesicular rash in the C4–C5 dermatomes. He was initially misdiagnosed with a tick-borne illness. Mean CSF values across all cases were WBC count 382/µL (SD ± 270), protein 177 mg/dL (SD ± 106), and glucose 52.7 mg/dL (SD ± 15.8). IV acyclovir was used in 15 of 17 cases, with oral acyclovir (41%) or valacyclovir (29%) as the most common step-down therapies. Mean treatment duration was 14 days, and average length of hospital stay was 6.4 days. All patients survived and made a full recovery. Spinal-dermatomal VZV meningitis can occur in immunocompetent adults, including cases with cervical involvement. Early recognition of the rash pattern and timely PCR testing are essential for accurate diagnosis and prompt antiviral therapy, which is associated with favorable outcomes.

01 Dec 2026·Radiology case reports

Malignant cerebral edema secondary to herpes simplex virus encephalitis requiring decompressive hemicraniectomy

Article

Author: Thakore, Gnan ; Forrest, Jonathan R ; Konney, Evans ; Thaker, Tapan

Herpes simplex encephalitis (HSE) is a severe viral infection of the central nervous system that most commonly affects the temporal lobes and limbic structures. Although most cases are managed medically with intravenous acyclovir, rare cases can rapidly progress to malignant cerebral edema, mass effect, and neurologic deterioration requiring surgical intervention. We report the case of a 57-year-old woman presenting with altered mental status, headache, vomiting, myalgias, and focal neurologic deficits. Initial computed tomography (CT) and CT angiography of the head and neck were unremarkable, but magnetic resonance imaging (MRI) demonstrated diffusion restriction involving the right mesial temporal lobe and insular cortex. Cerebrospinal fluid testing later confirmed HSE. Despite treatment with intravenous acyclovir, the patient developed worsening right hemispheric edema with progressive midline shift, requiring external ventricular drain placement followed by emergent right decompressive hemicraniectomy. She subsequently improved without persistent focal neurologic deficits and later underwent cranioplasty. Our case highlights the importance of early recognition with neuroimaging, close neurologic monitoring, repeat imaging, and timely neurosurgical intervention in severe herpes simplex encephalitis complicated by malignant cerebral edema.

51

News (Medical) associated with Acyclovir

21 Oct 2026

·www.biospace.com

Asahi Kasei Therapeutics Announces Late-Breaking Oral and Poster Presentations at IDWeek 2026

CARY, N.C. , Oct. 21, 2026 /PRNewswire/ -- Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei Corporation, with U.S. and European business headquarters in Cary, North Carolina, today announced a late-breaking oral presentation, a pipeline session presentation and five poster presentations at IDWeek 2026, taking place October 21-24, 2026, in Washington, D.C. Data presentations include two oral presentations: a resistance analysis from the Phase 3 PRIOH-1 trial evaluating a novel helicase-primase inhibitor (pritelivir) for immunocompromised adults with refractory herpes simplex virus (HSV) infection and an additional oral presentation on pritelivir in the New Antimicrobials in the Pipeline session. Three poster presentations featuring additional findings on pritelivir, including healthcare resource utilization outcomes from the Phase 3 PRIOH-1 trial, outcomes from the pritelivir early access program in immunocompromised patients with acyclovir- and foscarnet-refractory with or without resistant or foscarnet-intolerant HSV infection, and the impact of acid-reducing agents on pharmacokinetics of pritelivir. Additionally, there will be two poster presentations on a Phase 1 study for AIC468, evaluating the safety and pharmacokinetics targeting BK virus in adult kidney transplant patients and its potential to treat patients across BKV strains, with minimal risk of pre-existing resistance. These presentations highlight research advanced at AiCuris Anti-infective Cures AG, which is now part of Asahi Kasei Therapeutics. Oral presentation details are as follows: Title: (LB-2301.4) Resistance Analysis of Pritelivir, a Novel Helicase-Primase Inhibitor in the PRIOH-1 Phase 3 Trial in Immunocompromised Adults with Refractory Herpes Simplex Virus (HSV) Infection Session: Late Breaking Abstracts: HIV & STDs Presenter: Alexander L. Greninger Date and Time: Friday, October 23, 2026, 10:30 AM - 11:45 AM ET Location: 206 Title: Pritelivir for Refractory Herpes Simplex Virus (HSV) Infections in Immunocompromised Adults Session: New Antimicrobials in the Pipeline Presenter: Alexander Birkmann Date and Time: Friday, October 23, 2026, 8:48 AM - 9:00 AM ET Location: 206 Poster presentation details are as follows: Title: Reduced Healthcare Resource Utilization (HCRU) with Pritelivir Compared to Investigator's Choice Therapy (ICT) in Immunocompromised (IC) Patients Treated for Refractory Herpes Simplex Virus (HSV): Phase 3 PRIOH-1 Study Session: Novel Agents Presenter: Ryan Maves Date and Time: Thursday, October 22, 2026, 12:15 PM - 1:30 PM ET Location: Poster Hall B-C Title: Early Access Program (EAP) Experience of Pritelivir in the Treatment of Acyclovir- and Foscarnet-Refractory Herpes Simplex Virus (HSV) Infection in Immunocompromised (IC) Patients Session: Novel Agents Presenter: Yeon Joo (June) Lee Date and Time: Thursday, October 22, 2026, 12:15 PM - 1:30 PM ET Location: Poster Hall B-C Title: Safety and Pharmacokinetics of AIC468, a Novel Antisense Oligonucleotide Targeting BK-Virus Transcripts, Following Multiple Dosing in Healthy Volunteers Session: Clinical Trials Presenter: Susanne Bonsmann Date and Time: Saturday, October 24, 2026, 12:15 PM - 1:30 PM ET Location: Poster Hall B-C Title: AIC468, a Novel Antisense Oligonucleotide in Clinical Development for the Treatment of BKV in Kidney Transplant Recipients: Evidence of Broad BKV Strain Coverage and a Low Probability of Pre-Existing Drug Resistance Session: Virology Presenter: Peter Lischka Date and Time: Saturday, October 24, 2026, 12:15 PM - 1:30 PM ET Location: Poster Hall B-C Title: Impact of Acid-Reducing Agents on the Pharmacokinetics of Pritelivir, a Novel Oral Herpes Simplex Virus (HSV) Helicase-Primase Inhibitor Session: Virology Presenter: Susanne Bonsmann Date and Time: Saturday, October 24, 2026, 12:15 PM - 1:30 PM ET Location: Poster Hall B-C INDICATION AND IMPORTANT SAFETY INFORMATION FOR US AUDIENCE Indication HOVILPRI (pritelivir) tablets is indicated in immunocompromised adults for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacyclovir, or famciclovir. Important Safety Information Warnings and Precautions Drug Interactions with Acid-reducing Agents: Concomitant use of HOVILPRI with certain acid-reducing agents may reduce pritelivir exposure, potentially resulting in reduced therapeutic effect and development of resistance. Avoid concomitant use with certain proton pump inhibitors, and stagger concomitant use with H2-receptor antagonists and antacids. Adverse Reactions: In clinical studies, the adverse reaction (all grades) occurring in more than 5% of participants receiving HOVILPRI was headache, which occurred in 6% and 4% of the HOVILPRI and Investigator's Choice participants, respectively. Drug Interactions: Pritelivir is a breast cancer resistance protein (BCRP) inhibitor. Co-administration of HOVILPRI with a BCRP substrate may increase the plasma concentrations of the BCRP substrate, which may increase the risk of adverse reactions. Concomitant use of acid-reducing agents may elevate gastric pH and decrease the systemic bioavailability of HOVILPRI, which may reduce its effectiveness or cause drug resistance to HOVILPRI. Avoid concomitant use with esomeprazole or rabeprazole. Avoid concomitant use with omeprazole or lansoprazole at daily doses above 20 mg, or with pantoprazole at daily doses above 40 mg. Take HOVILPRI at least 2 hours before or 12 hours after H2-receptor antagonists. Take HOVILPRI at least 2 hours before or 2 hours after antacids. Please see full Prescribing Information at About Asahi Kasei Therapeutics Asahi Kasei Therapeutics is the global specialty pharmaceutical business of Tokyo-based Asahi Kasei. We are identifying, developing and commercializing innovative medicines for diseases with significant unmet medical needs. Drawing upon our strong heritage of scientific innovation, we are expanding therapeutic options and helping to positively impact health in immunology, nephrology, transplantation, and infectious diseases. For more information, visit: . About Asahi Kasei Asahi Kasei is a diversified global company that contributes to life and living for people around the world. Since its foundation in 1922, with businesses in ammonia and cellulose fiber, Asahi Kasei has consistently grown through proactive portfolio transformation to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to sustainability by providing solutions to the world's challenges across its three business sectors: Healthcare, Homes, and Material. For more information, visit . Asahi Kasei positions Pharmaceuticals as a First Priority business in its medium-term management plan, emphasizing value creation by expanding its research and development activities globally to deliver innovative therapeutic options worldwide. Contacts: Asahi Kasei Corporation Christian Okeefe christian.okeefe@ak-america.com Argot Partners David Rosen aktx@argotpartners.com View original content to download multimedia: SOURCE Asahi Kasei Therapeutics

Phase 3Clinical ResultPhase 1

12 Oct 2026

·www.fiercepharma.com

Asahi Kasei buyout yields novel FDA herpes nod in immunocompromised patients

Roughly half a year after the close of its deal to acquire Bayer spinout AiCurus, Asahi Kasei’s $920 million bet has paid off with an FDA green light. Late Friday, the FDA signed off on Asahi Kasei’s pritelivir tablets, to be marketed as Hovilpri as a new treatment for mucocutaneous lesions caused by herpes simplex virus (HSV) infection. Specifically, the helicase inhibitor—representing the first novel mechanism for an HSV treatment in nearly three decades—has been approved in immunocompromised adults whose infection is refractory, with or without documented resistance, with acyclovir, valacyclovir or famciclovir. The nod brings forward a new option to treat HSV-caused sores affecting the skin and mucous membranes and further bolsters the armamentarium for those herpes patients whose disease hasn’t responded to standard-of-care nucleoside analogue drugs. The drug was developed by AiCuris Anti-infective Cures, which Asahi Kasei bought for 780 million euros (then worth some $920 million) earlier this year. AiCuris, which spun out of German conglomerate Bayer back in 2006, has picked up other approvals in its history, too, including for the transplant infection preventative Prevymis, which was approved by the FDA in late 2017 and is currently marketed by Merck & Co. under an earlier licensing agreement . That medicine continues to function as a royalty stream for AiCuris. As for Hovilpri, Asahi Kasei said in an Oct. 9 release that it expects to make the drug available in the U.S. before the end of 2026. The company did not comment on its current pricing or access strategy around Hovilpri. The drug, taken at 100 mg daily by mouth after an initial 400-mg loading dose on day one of treatment, was cleared on data from the PRIOH-1 Part C phase 3 study, an open-label, comparator-controlled superiority trial that pitted Hovilpri against an investigator’s choice of treatment. Investigators were able to select between IV foscarnet, IV or topical cidofovir or 5% topical imiquimod for the control regimen. The study was able to knock out its primary endpoint after Hovilpri demonstrated superiority over the investigator’s choice control following 28 days of treatment, Asahi Kasei said Friday. By that 28-day mark, Hovilpri was also tied to a significantly higher rate of complete lesion healing at 63%, versus the 34% reported among the trial’s control arm. This lines up with an adjusted treatment difference of 28.4% between the study drug and investigator’s choice treatment cohort, according to Asahi Kasei. Up to day 42, Hovilpri charted response rates of 82%, compared to 42% in the comparator wing of the study. On the safety front, Asahi Kasei pointed out that in Part C of its phase 3 program, adverse reactions were reported less frequently in patients on Hovilpri at 22%, versus 54% among those who received an investigator’s choice of treatment. Discontinuations due to drug reactions also favored Hovilpri at a slim 2%, compared to 20% for the control. “Refractory HSV can be a serious clinical challenge for immunocompromised adults, a population with limited treatment options,” Carl Kraus, Asahi Kasei’s chief medical officer, said in a statement. “The approval of Hovilpri reflects years of clinical research in refractory HSV and reinforces our commitment to advancing scientifically differentiated medicines for patients whose conditions remain difficult to treat.” HSV represents a major global public health burden, with an estimated 3.8 billion people under the age of 50 infected with HSV-1—which typically results in sores around the mouth—in 2020, while around 520 million people between 15 and 49 years were living with the genital herpes variant HSV-2 that same year, per Asahi Kasei. For patients whose immune systems function as intended, HSV infection can often present without symptoms. But in immunocompromised adults, including hematopoietic stem cell and solid organ transplant recipients, people living with HIV and patients with cancers or autoimmune and inflammatory conditions, herpes infection can occur more frequently and be more severe, Asahi Kasei said. As an oral treatment, Asahi Kasei further believes Hovilpri could have an edge over the frequently intravenous treatments that are used as alternatives for immunocompromised patients who don’t respond to nucleoside analogue therapies like acyclovir. When it announced the close of its AiCuris deal earlier this year, Asahi Kasei said it expected Hovilpri could address some 15,000 immunocompromised patients in the U.S., with peak revenue for the drug “expected to exceed $400 million” in the mid- to late-2030s. Further ahead, AiCuris has wrapped up phase 1 testing on another asset coded AIC468 for BK virus infection in kidney transplant and hematopoietic stem cell transplant recipients, where Asahi Kasei said it has spied a potential market opportunity in excess of $1 billion. At the top of October, Asahi Kasei announced plans to wrap the AiCuris brand, plus those from prior buyouts of Veloxis Pharmaceuticals and Calliditas, under the singular Asahi Kasei Therapeutics banner.

Phase 3Clinical ResultDrug ApprovalAcquisitionLicense out/in

12 Oct 2026

·firstwordpharma.com

Asahi Kasei's recently acquired helicase primase inhibitor gets FDA approval for herpes lesions

About six months after Japanese drugmaker Asahi Kasei bought Aicuris for about €780 million, the treatment at the centre of the takeout has won FDA approval. The US regulator on Friday cleared Hovilpri (pritelivir), a helicase primase inhibitor, to treat immunocompromised patients who have mucocutaneous lesions caused by herpes simplex virus (HSV) that don't respond to standard-of-care therapies like acyclovir, valacyclovir or famciclovir. Asahi Kasei had proposed to acquire Aicuris in February, a few months after the latter reported that Hovilpri succeeded in the Phase III PRIOH-1 study involving 102 immunocompromised participants with HSV. Those in the experimental treatment arm received a loading dose of 400 mg on the first day of treatment followed by 100 mg each subsequent day until all lesions were healed, while the comparator group received investigator's choice of foscarnet, cidofovir or imiquimod. At day 28, patients taking Hovilpri achieved a lesion healing rate of 62.7%, a statistically significant result compared with the 34% healing rate seen with standard therapies. At the time, Aicuris said statistical superiority in lesion healing increased in patients receiving up to 42 days of treatment. The German company, founded in 2006 as a spin-off from Bayer, is also known for developing Prevymis (letermovir), a cytomegalovirus prevention therapy marketed by Merck & Co. After announcing its acquisition plans, Asahi said it will leverage its US transplant-centre channel and renal disease network to speed commercialisation of Hovilpri and future assets. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultAcquisitionDrug Approval

100 Deals associated with Acyclovir

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00222	Acyclovir	D06BB03 J05AB01 S01AD03	DB00787

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Keratitis, Herpetic	Japan	Nitto Medic Co., Ltd.	23 Jan 2007
Encephalitis, Herpes Simplex	South Korea	KYUNG DONG PHARMACEUTICAL Co., Ltd	07 Mar 1986
Herpes Labialis	South Korea	KYUNG DONG PHARMACEUTICAL Co., Ltd	07 Mar 1986
Chickenpox	United States	Pharmobedient Consulting LLC	25 Jan 1985
Herpes Zoster	China	Hubei Keyi Pharmaceutical Co., Ltd.	01 Jan 1985
Varicella Zoster Virus Infection	China	Hubei Keyi Pharmaceutical Co., Ltd.	01 Jan 1985
Herpes Genitalis	United States	Bausch Health US LLC	29 Mar 1982
Herpes Simplex	United Kingdom	Burroughs Wellcome	01 Jan 1981

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	United States	Glaxo Wellcome Plc	31 Aug 2001
AIDS-Related Complex	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001
Hairy Leukoplakia	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EBMT2026	Not Applicable	Varicella Zoster Virus Infection	100	800 mg BID two days a week	frmiqnnpgm(xeochjrdmq) = xqjptepcnn yloanppnsp (fgkmzgfdoz ) View more	Positive	22 Mar 2026
NCT05098938 (CTgov)	Phase 3	Herpes Labialis	2,020	Sitavig (Sitavig)	pzsmwtjczj(xipqjabwot) = pfehenyvof wurmfvjoqx (pqcpuxbrvm, djurczjcxf - xxlsfsfyae) View more	-	02 Sep 2025
				Placebo (Placebo)	pzsmwtjczj(xipqjabwot) = psthlgygfx wurmfvjoqx (pqcpuxbrvm, qmztahjftv - jqcugplybt) View more
EBMT2025	Not Applicable	Hematopoietic stem cell transplantation	334	quinolones+triazoles+acyclovir (Allo-HSCT)	cmthimgfbs(jhopyupaxw) = bzidxmaney mawaacvpkr (uqrlfzwwac ) View more	Positive	30 Mar 2025
				quinolones+acyclovir (Auto-HSCT)	cmthimgfbs(jhopyupaxw) = peexelpyzk mawaacvpkr (uqrlfzwwac ) View more
NCT02073097 (CTgov)	Phase 1/2	Diffuse Large B-Cell Lymphoma	48	Pegfilgrastim+Acyclovir+Cyclophosphamide+carfilzomib+prednisone+doxorubicin hydrochloride+Vincristine sulfate+Rituximab	sqjtrcmiox = tsmpkukobj xddazupqsi (ljhrvintvc, bvxpqxqxjw - iqzvhupnrl) View more	-	29 May 2024
EBMT2024	Not Applicable	Adenovirus Infections, Human	757	PTCy+sirolimus	iedzekzgrn(hebgheeufo) = xbvsjdoynl bzjzuevdgf (kdihhetkwb ) View more	Positive	14 Apr 2024
NCT04988646 (CTgov)	Not Applicable	-	56	Acyclovir (Acyclovir 200 mg Tablet)	aqccrghqyy(icohzwatvx) = zsagwagfbe awzxnbzivi (typjqfmmzk, 244.06) View more	-	08 Feb 2023
				Zovirax (Zovirax® 200 mg Tablet)	aqccrghqyy(icohzwatvx) = kiazqarcgg awzxnbzivi (typjqfmmzk, 258.18) View more
IRCT20141124020073N2 (Pubmed \| Clin Exp Dent Res)	Phase 3	Herpes Labialis	60	Acyclovir nanofiber patch	ylhltmreul(xqgcowygul) = gmmiaoqfeb ookenqiwji (xzyhvtxcnc ) View more	-	05 Dec 2021
				Placebo nanofiber patch	ylhltmreul(xqgcowygul) = muptokhhcv ookenqiwji (xzyhvtxcnc ) View more
NCT02265913 (CTgov)	Phase 3	Herpes Labialis	4,076	Acyclovir 5 percent (Perrigo) (Test Product)	syqczoibnd(lsebswmsrc) = wypnmwnnzn dikskdturb (sfwhhkbzuk, 80.660) View more	-	05 Jan 2021
				Acyclovir (Reference Product)	syqczoibnd(lsebswmsrc) = wqgyyshryd dikskdturb (sfwhhkbzuk, 82.840) View more
NCT00495716 (CTgov)	Phase 4	Herpes Genitalis	72	acyclovir (Episodic Treatment Arm)	furyqfguhw(jzztkpbhbd) = uzgcvkejbh rizebuvfkx (nwzudxigaf, kstcgevrjt - mhicqixkaz) View more	-	29 Jan 2020
				acyclovir (Suppressive Therapy Arm)	furyqfguhw(jzztkpbhbd) = ejjcdupvcc rizebuvfkx (nwzudxigaf, adjmqqocmg - crztqyorjs) View more
NCT02152358 (Pubmed \| JAMA Intern Med)	Phase 4	Herpesviridae Infections	238	Intravenous Acyclovir	kmqdgshfvp(mxjeuqoskk) = pvssckjpkg skquyztqcv (pfsrpdsfuj ) View more	Negative	16 Dec 2019
				Placebo	kmqdgshfvp(mxjeuqoskk) = vkspdxyvsj skquyztqcv (pfsrpdsfuj ) View more